Land: Irland
Sprache: Englisch
Quelle: HPRA (Health Products Regulatory Authority)
Captopril; Hydrochlorothiazide
Rowex Ltd
C09BA; C09BA01
Captopril; Hydrochlorothiazide
50/25mg milligram(s)
Tablet
Product subject to prescription which may be renewed (B)
ACE inhibitors and diuretics; captopril and diuretics
Not marketed
1998-10-16
PACKAGE LEAFLET: INFORMATION FOR THE USER CAPTOR-HCT 25MG/12.5MG & 50MG/25MG TABLETS CAPTOPRIL & HYDROCHLOROTHIAZIDE READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Captor-HCT is and what it is used for 2. What you need to know before you take Captor-HCT 3. How to take Captor-HCT 4. Possible side effects 5. How to store Captor-HCT 6. Contents of the pack and other information 1 WHAT CAPTOR-HCT IS AND WHAT IT IS USED FOR Captor-HCT is used to treat: • HIGH BLOOD PRESSURE This medication is made up of two different active substances: captopril and hydrochlorothiazide. Captopril belongs to the ACE inhibitors medicine group (angiotensin-converting enzyme inhibitors). Captopril expands your blood vessels. This reduces your blood pressure and makes it easier for your heart to pump blood to all body parts. Hydrochlorothiazide is a water pill (diuretic). It increases the amount of salt and water you lose in your urine. This also results in a fall in blood pressure. 2 WHAT YOU NEED TO KNOW BEFORE YOU TAKE CAPTOR-HCT DO NOT TAKE CAPTOR-HCT: • if you are ALLERGIC to - captopril, hydrochlorothiazide or - any of the other ingredients of this medicine (listed in section 6) or - other ACE inhibitors or to any other sulphonamide derivatives • if during earlier ACE inhibitor use you had SWELLING OF THE FACE, LIPS, TONGUE and/or THROAT with difficulty swallowing or breathing Do not take Captor-HCT if you had any of these reactions - without a known cause or - if it has been confirmed that you have a Lesen Sie das vollständige Dokument
Health Products Regulatory Authority 24 November 2019 CRN008X7G Page 1 of 14 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Captor-HCT 50mg/25mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains captopril 50 mg and hydrochlorothiazide 25 mg. Excipient(s) with known effect: contains lactose monohydrate 68.7mg For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet. White octagonal tablets with a one-sided crossed score notch and the opposite convex side has the mark ‘Cc’ engraved on it. The score-notch allows the tablet to be divided into equal halves or quarters. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of essential hypertension. This fixed dose combination is indicated in patients whose blood pressure is not adequately controlled by captopril alone or hydrochlorothiazide alone. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION CAPTOR-HCT can be administered in a single or two divided doses/day with or without food in patients whose blood pressure is not adequately controlled by captopril alone or hydrochlorothiazide alone. A maximum daily dose of 50 mg captopril/25 mg hydrochlorothiazide should not be exceeded. If satisfactory reduction of blood pressure has not been achieved, additional antihypertensive medication may be added (see sections 4.3, 4.4, 4.5 and 5.1). Adults: the administration of the fixed combination of captopril and hydrochlorothiazide is usually recommended after dosage titration with the individual components. The usual maintenance dose is 50/25 mg, once a day, in the morning. When clinically appropriate a direct change from monotherapy to the fixed combination may be considered. Renal impairment: Creatinine clearance between 30 and 80 mL/min: the initial dose is usually 25/12.5 mg once a day, in the morning. The combination captopril/hydrochlorothiazide is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min). Special populations: in salt/volume depleted patients, elderly pati Lesen Sie das vollständige Dokument